Big Moves: June 16, 2025
What moved today and why? Roku and Sarepta Therapeutics
Riding The Bear
I’ve been listening to an excellent interview with Steve Ballmer of Microsoft fame on the Acquired podcast. At one point, he talks about how they felt their relationship with IBM was like riding the bear. In the 1980s, Big Blue was considered “the moon and the stars.” From Microsoft’s perspective, they had to "hang on to IBM" because if they "let go," IBM "might trample us" or "stomp us out like a bug." This meant they felt they had to "play with them" to secure their future.
While not a perfect analogy, this all came to mind while pulling together a note on the announcement that Roku is partnering with Amazon on data and advertising. It could be good—really good. But getting in tight with Amazon isn’t without its risks, as the company has been known to exert its leverage at unfortunate moments for its partners. Read more below and in Roku Stock Surges on Strategic Amazon Ads Partnership.
For new readers, one of the main motivations behind starting Big Price Moves Explained was to have a reason to actively engage with AI on a daily basis—learning by doing. I maintain active editorial oversight over topic selection, model, and platform choices, but pretty much everything below this point is written by AI.
A quick preview of Monday’s notable moves:
Strategic Partnerships: Roku* shares surged following the announcement of an exclusive partnership with Amazon Ads, poised to expand its CTV footprint and enhance advertising efficiency in the U.S.
Safety Concerns: Sarepta Therapeutics* stock plummets as safety concerns over Elevidys treatment lead to shipment suspension and multiple brokerage downgrades.
* These companies have the pros and cons discussed on their earnings calls or in other materials summarized in the Read section below.
Skim
This is where you come to quickly see if anything interesting is happening with names you care about. Think of it as informative advertising.
Sarepta Therapeutics Inc (SRPT) - Biotechnology (-42.12%) Sarepta Therapeutics Inc (SRPT) is down -42.12% on June 16, 2025, primarily due to multiple downgrades from several brokerages following the announcement of a second patient death related to its Elevidys treatment. The underlying issue is the safety concerns surrounding Elevidys, which led Sarepta to temporarily suspend shipments of the drug for non-ambulatory patients with Duchenne muscular dystrophy. This suspension and the subsequent downgrades, including Morgan Stanley's downgrade to Equal Weight and a significant reduction in price targets by BMO Capital, HC Wainwright, and Piper Sandler, have contributed to the sharp decline in the stock price. Sources: MT Newswires, The Fly, Benzinga
Roku Inc (ROKU) - Broadcasting (+10.43%) Roku Inc (ROKU) shares rose by 10.43% on Monday due to the announcement of an exclusive partnership with Amazon Ads. This collaboration is set to create the largest authenticated Connected TV (CTV) footprint in the U.S., giving advertisers access to approximately 80 million U.S. CTV households through Amazon's demand-side platform (DSP). The partnership aims to enhance advertising reach and efficiency, promising advertisers up to 40% more unique viewers with the same budget and reducing ad repetition by nearly 30%. Sources: Yahoo! Finance, AOL.com, Bloomberg News, Benzinga
Powered by BigData.com, Big Price Moves Explained; text generated by GPT-4o
Read
In this section we offer a bit more detail in a couple of featured names.
Roku Inc (ROKU) - Broadcasting (82.17 | +10.43%)
Amazon, Roku Strike Exclusive Ad Pact, Creating Largest Authenticated TV Audience
Roku shares surged approximately 10.8% following the announcement of an exclusive partnership with Amazon Ads that creates the largest authenticated connected TV footprint in the United States, reaching an estimated 80 million households. This strategic collaboration allows advertisers to access Roku's platform through Amazon's DSP advertising platform, with early trials showing 40% more unique viewers reached with the same budget and a 30% reduction in ad frequency.
Strategic Benefits for Roku
The partnership significantly strengthens Roku's platform business model by positioning it as "the most addressable platform for CTV activation" through Amazon DSP, directly supporting the company's core growth directives of scale, engagement, and monetization. This exclusive designation creates a competitive advantage that validates Roku's strategic shift away from operating its own DSP toward partnering with external demand sources.
Financial markets responded enthusiastically to the announcement, with Roku stock climbing to $82.48, representing a 10.84% increase and its highest close since March 2025. The collaboration enhances Roku's value proposition to advertisers by providing access to Amazon's "trillions of shopping, streaming, and browsing signals" combined with Roku's authenticated reach, enabling premium pricing for inventory while delivering measurably better outcomes for advertisers.
Performance Improvements in Ad Targeting
The partnership's custom identity resolution service allows Amazon DSP to recognize logged-in viewers across Roku's operating system and devices, enabling advertisers to reach the same viewer deterministically across different streaming channels. This technology addresses two critical challenges in CTV advertising: fragmentation and over-frequency. Early testing demonstrated substantial benefits with advertisers achieving three times more value from their advertising expenditures compared to previous targeting methods.
The integration enhances addressability across major streaming applications including The Roku Channel, Prime Video, and other leading services from Disney, FOX Corporation, Paramount, Tubi, and Warner Bros Discovery. This technology is expected to be made available to advertisers using Amazon's demand-side platform by the fourth quarter of 2025, strategically timed for the critical Q4 advertising season.
Competitive Positioning Impact
The exclusive partnership effectively neutralizes competitive threats, particularly from The Trade Desk's Ventura connected TV operating system which industry observers had viewed as "a shot across the bow to the Roku business." By securing Amazon DSP as an exclusive partner for authenticated reach, Roku creates a significant moat against emerging competitors while protecting its market position against Amazon Fire TV, Google TV, and other platforms. Bloomberg Intelligence analyst Geetha Ranganathan noted that fears about competitive threats to Trade Desk's ad budgets are "only about to get stronger with this new pact," highlighting how the partnership shifts competitive dynamics in Roku's favor.
Strengthens Roku's position as the leading streaming platform that commands nearly half of all TV streaming time in the U.S.
Creates switching costs for advertisers and increases Roku's strategic importance in the broader advertising ecosystem
Improves revenue quality by providing access to Amazon's performance-driven advertising budgets that have historically been more resilient during economic downturns
Key Risks and Dependencies
Despite the partnership's benefits, it introduces significant strategic vulnerabilities for Roku. The company now faces increased dependence on Amazon, which remains one of its primary competitors in the streaming device market with Amazon Fire TV gaining meaningful market share. This creates an inherent conflict where Roku becomes strategically reliant on a direct rival that simultaneously competes for the same living room real estate.
The partnership requires unprecedented levels of user data sharing through the custom identity resolution service, potentially providing Amazon with detailed insights into Roku's user behavior patterns and platform performance. Additional concerns include revenue concentration risk, with projections suggesting Amazon could contribute substantial revenue to Roku within 18 months, and potential regulatory scrutiny given that the partnership creates a market concentration representing more than 80% of U.S. CTV households.
Guided by Big Price Moves Explained; Sourced and written with Perplexity.ai in Deep Research mode [link with citations]
Sarepta Therapeutics Inc (SRPT) - Biotechnology (20.94 | -42.12%)
Sarepta Stock Plunges After Patient Death
Sarepta Therapeutics (SRPT) stock experienced its worst single-day performance of 2025 on June 16, plummeting 42.12% following the announcement of a second patient death linked to its Duchenne muscular dystrophy gene therapy Elevidys, significantly outpacing previous major declines including the May 6-7 two-day drop of approximately 42%.
Second Patient Death Impact
The second fatality involved a patient who died from acute liver failure while receiving Elevidys treatment, mirroring the first death reported in March 2025. Both cases occurred specifically in non-ambulatory Duchenne muscular dystrophy patients who had lost the ability to walk. This tragic development prompted Sarepta to immediately suspend shipments of Elevidys for non-ambulatory patients and pause dosing in the ENVISION Phase III confirmatory trial. The company has assembled an independent panel of Duchenne and liver specialists to evaluate enhanced immunosuppression protocols that would include adding sirolimus to the treatment regimen, while maintaining unchanged protocols for ambulatory patients.
Analyst Downgrades
The wave of analyst downgrades following the second Elevidys-related death was swift and severe, with multiple major firms slashing their ratings and price targets. Morgan Stanley downgraded Sarepta from Overweight to Equal Weight, reducing its price target by 65% from $113 to $40, while completely removing non-ambulatory patient revenues from their financial models. HC Wainwright delivered the harshest assessment with a rare "Sell" rating and a $10 price target, expressing serious concerns about Elevidys's risk profile for all DMD patients.
Other significant downgrades included BMO Capital Markets (Outperform to Market Perform, $120 to $70), Piper Sandler (Overweight to Neutral, $70 to $36), and Bank of America Securities (Buy to Neutral, $76 to $28). Despite the overwhelmingly negative sentiment, Needham & Company maintained its Buy rating while still cutting its price target by 60% from $125 to $50. Trading volume surged to 27.5 million shares—14 times the daily average—as investors rushed to exit positions amid the rapidly deteriorating outlook.
Safety Measures Implemented
In response to the second fatal case of acute liver failure, Sarepta implemented immediate safety protocols beyond just suspending shipments. The company's commercial suspension specifically targets non-ambulatory patients, who appear to be at higher risk, as both fatalities occurred in this population. Additionally, Sarepta has formed a specialized team of Duchenne and liver health experts to develop an enhanced immunosuppressive regimen that would incorporate sirolimus alongside existing protocols.
Acute liver injury is a recognized risk with adeno-associated virus (AAV)-based gene therapies like Elevidys, with approximately 30% of patients experiencing elevated liver enzymes within 90 days of treatment, though these typically respond to increased steroid doses. The FDA has stated it is "treating this situation with the highest level of concern" and will "take all appropriate regulatory actions" as the company works to address these safety issues.
Historical Stock Declines
The June 16 collapse represents the culmination of a disastrous year for Sarepta, with the stock down 84.1% since January 2025, falling from $124.09 to approximately $20.64. Prior to this catastrophic drop, the company had already weathered significant declines, including a two-day selloff on May 6-7 triggered by disappointing Q1 earnings and the appointment of Elevidys critic Vinay Prasad to lead the FDA's Center for Biologics Evaluation and Research. The current price marks a nine-year low for the stock, erasing years of gains and pushing shares to levels not seen since 2016.
Guided by Big Price Moves Explained; Sourced and written with Perplexity.ai in Deep Research mode [link with citations]
Disclaimer: The information contained in this newsletter is intended for educational purposes only and should not be construed as financial advice. Please consult with a qualified financial advisor before making any investment decisions. Additionally, please note that we at e/r/c advisors may or may not have a position in any of the companies mentioned herein. This is not a recommendation to buy or sell any security. The information contained herein is presented in good faith on a best efforts basis; note that most of the writing is undertaken by AI—rely on it at your own risk.